High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma
暂无分享,去创建一个
A. Iagaru | C. Mari Aparici | A. Chen | J. Carrasquillo | K. Pacak | A. Civelek | R. Hicks | D. Taïeb | T. Hope | I. Virgolini | S. Basu | J. Strosberg | B. Shulkin | A. Avram | N. Pandit-Taskar | C. Millo | W. D. de Herder | D. Pryma | B. Mittal | F. Lin | J. Crona | J. Del Rivero | Joseph S. Dillon | A. Jha | Mayank Patel | J. del Rivero | M. Patel | Frank I. Lin | Joakim Crona | Abhishek Jha | Jaydira Del Rivero
[1] K. Pacak,et al. Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma , 2020, Current Treatment Options in Oncology.
[2] Priyanka Verma,et al. 177Lu-DOTATATE therapy in metastatic/inoperable pheochromocytoma-paraganglioma , 2020, Endocrine connections.
[3] S. Severi,et al. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study , 2020, European Journal of Nuclear Medicine and Molecular Imaging.
[4] B. Mittal,et al. ‘Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta‐analysis’ , 2019, Clinical endocrinology.
[5] R. Sahoo,et al. Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[6] K. Pacak,et al. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups , 2019, Endocrine-Related Cancer.
[7] R. M. Metselaar,et al. Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE. , 2019, European journal of endocrinology.
[8] A. Sundin,et al. Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with 177Lu-DOTATATE , 2019, Cancers.
[9] N. Stambler,et al. Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma , 2018, The Journal of Nuclear Medicine.
[10] E. Krenning,et al. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] W. Young,et al. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years , 2017, The Journal of clinical endocrinology and metabolism.
[12] S. Grozinsky-Glasberg,et al. Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma , 2017, The Journal of clinical endocrinology and metabolism.
[13] E. Krenning,et al. Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors , 2017, Clinical Cancer Research.
[14] B. Khoo,et al. Peptide Receptor Radionuclide Treatment and (131)I‐MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas , 2017, Journal of surgical oncology.
[15] J. Berlin,et al. Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors , 2017, The New England journal of medicine.
[16] T. Akhurst,et al. High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[17] J. Carrasquillo,et al. I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma. , 2016, Seminars in nuclear medicine.
[18] A. Mcewan,et al. The Challenges of Treating Paraganglioma Patients with 177Lu-DOTATATE PRRT: Catecholamine Crises, Tumor Lysis Syndrome and the Need for Modification of Treatment Protocols , 2015, Nuclear Medicine and Molecular Imaging.
[19] Y. Menda,et al. Feasibility and advantage of adding 131I-MIBG to 90Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors , 2014, EJNMMI Research.
[20] A. Tabarin,et al. One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. , 2013, The Journal of clinical endocrinology and metabolism.